Luye Pharma Group Ltd
HKEX:2186
Intrinsic Value
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling pharmaceutical products. [ Read More ]
The intrinsic value of one
Luye Pharma Group Ltd
stock under the Base Case scenario is
3.28
HKD.
Compared to the current market price of 2.69 HKD,
Luye Pharma Group Ltd
is
Undervalued by 18%.
Luye Pharma Group Ltd's market capitalization is 9.5B HKD.
Luye Pharma Group Ltd stock price is 2.69 HKD.
Luye Pharma Group Ltd stock price (2.69 HKD) is 18% less than its Intrinsic Value (3.28 HKD).
Luye Pharma Group Ltd stock (1.43 HKD) is 47% less than its price (2.69 HKD). Open DCF Valuation
Luye Pharma Group Ltd stock price (2.69 HKD) is 48% less than its Relative Value (5.13 HKD). Open Relative Valuation
Luye Pharma Group Ltd has upside potential of 12% compared to the average analyst price target.
Open Wall St Estimates
Luye Pharma Group Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 6% to 5%.
Luye Pharma Group Ltd's Revenue has grown by 3% over the past 12 months.
Luye Pharma Group Ltd's Revenue has been growing by 4% per year for the last 3 years.
Luye Pharma Group Ltd's ROE (Return on Equity) has decreased in the last 3 years from 8% to 5%.
Luye Pharma Group Ltd has positive Operating Income for the last twelve months.
Luye Pharma Group Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
Luye Pharma Group Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 5%.
Luye Pharma Group Ltd has positive Net Income for the last twelve months.
Luye Pharma Group Ltd's short-term assets (11B CNY) exceed its short-term liabilties (8B CNY).
Luye Pharma Group Ltd has a very low three-year average ROE (Return on Equity): 4%. The company is not efficient at transforming stockholders' equity into net income.
Luye Pharma Group Ltd has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
Luye Pharma Group Ltd's long-term assets (25B CNY) exceed its long-term liabilties (13B CNY).
Luye Pharma Group Ltd has positive Free Cash Flow for the last twelve months.
Luye Pharma Group Ltd has negative Net Debt. This means that the company has more cash and short-term investments (6B CNY) than debt (3B CNY).
Luye Pharma Group Ltd has positive Gross Profit for the last twelve months.
Luye Pharma Group Ltd's Altman Z-Score is very low and is equal to 1.27.
Luye Pharma Group Ltd's D/E (Debt to Equity) is very low and is equal to 0.26.
Luye Pharma Group Ltd generates enough operating income (1B CNY) to cover interest payments on its debt (368m CNY).
Valuation Backtest
Luye Pharma Group Ltd
Run backtest to discover the historical profit from buying and selling
Luye Pharma Group Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Luye Pharma Group Ltd
Balance Sheet Decomposition
Luye Pharma Group Ltd
| Current Assets | 10.7B |
| Cash & Short-Term Investments | 6.1B |
| Receivables | 2.4B |
| Other Current Assets | 2.2B |
| Non-Current Assets | 14.8B |
| Long-Term Investments | 2B |
| PP&E | 5.2B |
| Intangibles | 7.4B |
| Other Non-Current Assets | 304.2m |
| Current Liabilities | 8.1B |
| Accounts Payable | 767.2m |
| Other Current Liabilities | 7.4B |
| Non-Current Liabilities | 4.8B |
| Long-Term Debt | 3.2B |
| Other Non-Current Liabilities | 1.6B |
Earnings Waterfall
Luye Pharma Group Ltd
|
Revenue
|
6.1B
CNY
|
|
Cost of Revenue
|
-1.9B
CNY
|
|
Gross Profit
|
4.2B
CNY
|
|
Operating Expenses
|
-2.9B
CNY
|
|
Operating Income
|
1.3B
CNY
|
|
Other Expenses
|
-764.9m
CNY
|
|
Net Income
|
532.6m
CNY
|
Free Cash Flow Analysis
Luye Pharma Group Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Luye Pharma Group Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Luye Pharma Group Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Luye Pharma Group Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Luye Pharma Group Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Luye Pharma Group Ltd
According to Wall Street analysts, the average 1-year price target for
Luye Pharma Group Ltd
is 3 HKD
with a low forecast of 2.42 HKD and a high forecast of 3.92 HKD.
Shareholder Return
Price
Luye Pharma Group Ltd
| Average Annual Return | -12.6% |
| Standard Deviation of Annual Returns | 18.5% |
| Max Drawdown | -73% |
| Market Capitalization | 9.5B HKD |
| Shares Outstanding | 3 761 669 888 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Luye Pharma Group Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling pharmaceutical products. The company is headquartered in Yantai, Shandong. The company went IPO on 2014-07-09. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The firm operates its business mainly in Mainland China.
Contact
IPO
Employees
Officers
The intrinsic value of one
Luye Pharma Group Ltd
stock under the Base Case scenario is
3.28
HKD.
Compared to the current market price of 2.69 HKD,
Luye Pharma Group Ltd
is
Undervalued by 18%.
You don't have any saved screeners yet
